Abstract
Non-small cell lung cancer (NSCLC) is currently the leading cause of cancer death worldwide. NSCLC patients with epidermal growth factor receptor (EGFR) mutations were treated with EGFR-tyrosine kinase inhibitor (TKI), but EGFR mutations combined with other genes had a shorter survival. However, the P53 gene mutation is a common combined mutation in patients with NSCLC with EGFR gene mutation. This review summarizes the development of targeted NSCLC for EGFR with P53 mutations.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
